Opinion on R&D

Published within

« | ... | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: Effexor XR is deemed effective

Wyeth has released the findings of the study, which pooled together results of eight double-blind studies and compared Effexor XR to a leading serotonin selective re-uptake inhibitor. Although the drug's sales should be high it could suffer at the hands of strong competition from Lilly's duloxetine.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Wyeth: Prempro linked with dementia

A recent study published in the Journal of the American Medical Association has shown that Wyeth's hormone combination therapy Prempro increases the risk of probable dementia in postmenopausal women aged 65 years or older. Further studies are needed to establish the role of estrogen therapies in the onset of Alzheimer's disease.

Published By Datamonitor
29 May 2003
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
Expert View
Expert View

Xigris: Lilly's sepsis flop misses out

Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?

Published By Datamonitor
22 Mar 2002
CommentWire
CommentWire

Xolair: breathing easy over FDA approval

Xolair, developed by Genentech, Novartis and Tanox, reduces the number of attacks in severe allergic asthmatics. However prescribing restrictions, safety concerns and high cost are expected to limit sales to $593 million by 2010. The drug's best chance of success is through label extensions for pediatric use and for allergic rhinitis.<BR />

Published By Datamonitor
19 May 2003
CommentWire
CommentWire

Zimmer: big advances through tiny holes

Zimmer has released positive preliminary results for its two-incision minimally invasive hip arthroplasty system, and also plans to open a training facility teaching surgeons how to implant these systems. But while the system can radically reduce recovery time, it involves an extremely difficult technique that most orthopaedic surgeons are unlikely to adopt.

Published By Datamonitor
24 Jul 2002

« | ... | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | » »|

No help is available.